SNCE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNCE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Science 37 Holdings's enterprise value is $-21.16 Mil. Science 37 Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $60.26 Mil. Therefore, Science 37 Holdings's EV-to-Revenue for today is -0.35.
The historical rank and industry rank for Science 37 Holdings's EV-to-Revenue or its related term are showing as below:
During the past 3 years, the highest EV-to-Revenue of Science 37 Holdings was 127.61. The lowest was -4.26. And the median was -0.36.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-07), Science 37 Holdings's stock price is $5.75. Science 37 Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $10.32. Therefore, Science 37 Holdings's PS Ratio for today is 0.56.
The historical data trend for Science 37 Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Science 37 Holdings Annual Data | |||||||
Trend | Jun20 | Jun21 | Dec22 | ||||
EV-to-Revenue | - | - | -0.83 |
Science 37 Holdings Quarterly Data | ||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 1.09 | -0.83 | -0.74 | -0.63 | -0.14 |
For the Health Information Services subindustry, Science 37 Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Science 37 Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Science 37 Holdings's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Science 37 Holdings's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -21.156 | / | 60.261 | |
= | -0.35 |
Science 37 Holdings's current Enterprise Value is $-21.16 Mil.
Science 37 Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Science 37 Holdings (NAS:SNCE) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Science 37 Holdings's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 5.75 | / | 10.32 | |
= | 0.56 |
Science 37 Holdings's share price for today is $5.75.
Science 37 Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Science 37 Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Troy Bryenton | officer: Chief Technology Officer | 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709 |
Christine A Pellizzari | officer: Chief Legal Officer | 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Autenried Paul Von | director | BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543 |
Michael Shipton | officer: Chief Commercial Officer | 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709 |
Adam Goulburn | director | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
Thermo Fisher Scientific Powder Us Holdings Corp. | 10 percent owner | 168 THIRD AVENUE, WALTHAM MA 02451 |
Thermo Fisher Scientific Inc. | 10 percent owner | 168 THIRD AVENUE, WALTHAM MA 02451 |
Neil Tiwari | director | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
Darcy Forman | officer: Chief Delivery Officer | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
David Coman | director, officer: Chief Executive Officer | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
Jonathan Cotliar | officer: Chief Medical Officer | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
Steven Geffon | officer: Chief Commercial Officer | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
De Silva Bhooshitha B. | director | PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Mike Zaranek | officer: Chief Financial Officer | C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019 |
Ppd, Inc. | 10 percent owner | 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331 |
From GuruFocus
By Marketwired • 10-24-2023
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 09-20-2023
By GuruFocus Research • 11-07-2023
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 04-25-2023
By GlobeNewswire • 11-10-2023
By GlobeNewswire • 07-07-2023
By Marketwired • 10-06-2023
By Marketwired • 08-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.